On September 2, 2025 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, reported that MacroGenics’ President & Chief Executive Officer, Eric Risser, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:30am ET in New York, NY (Press release, MacroGenics, SEP 2, 2025, View Source [SID1234655648]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain an archived replay of the webcast on its website for 30 days.

On September 2, 2025 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 1:00 p.m. EDT on Monday, September 8, at the H.C. Wainwright 27th Annual Global Investment Conference (Press release, Puma Biotechnology, SEP 2, 2025, View Source [SID1234655679]). The conference will be held September 8–10, 2025 at the Lotte New York Palace Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Company’s website at View Source The presentation will be archived on the website and available for 30 days.

On September 2, 2025 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that Robert M. Davis, chairman and chief executive officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, Sept. 8, 2025, at 2:35 p.m. EDT (Press release, Merck & Co, SEP 2, 2025, View Source [SID1234655649]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

On September 2, 2025 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that the time of management’s presentation at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8th – 10th, 2025 in New York City, has been changed to 10:30 AM ET on September 9 (Press release, Anixa Biosciences, SEP 2, 2025, https://ir.anixa.com/news/detail/1096/anixa-biosciences-announces-time-change-for-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference [SID1234655633]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings during the conference.

Details of the presentation are as follows:

Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 9, 2025
Time: 10:30 AM ET
Location: Kennedy I – 4th Floor, Lotte New York Palace Hotel
Webcast: View Source

On September 2, 2025 NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, reported that Company management will participate in a fireside chat at following conference (Press release, Nanobiotix, SEP 2, 2025, View Source [SID1234655650]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 27th Annual Global Investment Conference
Date: Tuesday, September 9th, 2025
Time: 9:00 am EDT / 3:00 pm CEST
Location: New York, NY
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix & Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here

The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. The replay of the webcast will be available following the event.